Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$145M |
| 2 |
Immatics
IMTX
|
+$43.5M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$38.6M |
| 4 |
Coca-Cola
KO
|
+$35.8M |
| 5 |
Caesars Entertainment
CZR
|
+$30.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$78.3M |
| 2 |
ACLX
Arcellx
ACLX
|
+$57.6M |
| 3 |
Royalty Pharma
RPRX
|
+$52.8M |
| 4 |
AT&T
T
|
+$50.3M |
| 5 |
UnitedHealth
UNH
|
+$40.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.9% |
| 2 | Consumer Discretionary | 8.93% |
| 3 | Technology | 8.81% |
| 4 | Financials | 5.59% |
| 5 | Communication Services | 4.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CRH
CRH
$63.2B
| $40.4M | 1.38% |
436,394
-102,500
| -19% | -$9.86M |
|
|
27
UnitedHealth
UNH
$350B
| $38M | 1.3% |
75,198
-71,647
| -49% | -$40.7M |
|
28
Oracle
ORCL
$422B
| $37.7M | 1.29% |
226,318
-10,776
| -5% | -$1.91M |
|
|
29
Immatics
IMTX
$1.22B
| $36M | 1.23% |
+5,065,277
| New | +$43.5M |
|
30
Boston Scientific
BSX
$73B
| $35.5M | 1.21% |
397,679
+145,990
| +58% | +$12.9M |
|
31
GE Aerospace
GE
$361B
| $33.5M | 1.14% |
200,662
| – | – |
|
|
32
Rocket Pharmaceuticals
RCKT
$385M
| $32.3M | 1.1% |
+2,566,951
| New | +$38.6M |
|
33
Erasca
ERAS
$6.17B
| $30.9M | 1.05% |
12,315,004
-1,453,035
| -11% | -$3.98M |
|
34
McDonald's
MCD
$192B
| $30M | 1.02% |
103,638
| – | – |
|
35
Verizon
VZ
$205B
| $29.5M | 1.01% |
738,414
-20,260
| -3% | -$855K |
|
36
CALL
TG Therapeutics
TGTX
$8.31B
| $29.5M | 1.01% |
+980,000
| New | +$28.1M |
|
37
Boeing
BA
$169B
| $27.5M | 0.94% |
+155,197
| New | +$24.4M |
|
|
38
Caesars Entertainment
CZR
$6.06B
| $25.8M | 0.88% |
+772,412
| New | +$30.6M |
|
|
APLS
39
DELISTED
Apellis Pharmaceuticals
APLS
| $25.3M | 0.86% |
+793,187
| New | +$23.9M |
|
40
Datadog
DDOG
$84.6B
| $25.2M | 0.86% |
+176,450
| New | +$24.2M |
|
|
CTNM
41
Contineum Therapeutics
CTNM
$647M
| $25.2M | 0.86% |
1,720,000
| – | – |
|
42
NVIDIA
NVDA
$5.2T
| $24.3M | 0.83% |
+180,756
| New | +$24.9M |
|
43
ProKidney
PROK
$336M
| $20.9M | 0.71% |
12,341,266
| – | – |
|
44
Abeona Therapeutics
ABEO
$348M
| $20.5M | 0.7% |
3,685,503
| – | – |
|
45
Johnson & Johnson
JNJ
$651B
| $20.2M | 0.69% |
139,986
+1,539
| +1% | +$238K |
|
46
United Airlines
UAL
$36.7B
| $19.5M | 0.66% |
+200,650
| New | +$17M |
|
47
Biogen
BIIB
$32B
| $17.7M | 0.6% |
115,436
+85,490
| +285% | +$14.4M |
|
48
Domino's
DPZ
$11.3B
| $16.1M | 0.55% |
+38,340
| New | +$16.8M |
|
49
Fulcrum Therapeutics
FULC
$292M
| $15.7M | 0.53% |
3,338,466
+2,155,675
| +182% | +$7.95M |
|
50
InflaRx
IFRX
$309M
| $14.2M | 0.48% |
5,733,910
| – | – |
|
Similar funds
Aaron Cowen's Q4 2024 Portfolio in Review
As of Q4 2024, Aaron Cowen held 115 positions worth $2.93B, down 6.1% from $3.13B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Aaron Cowen's Q4 2024 filing shows 17 new, 19 increased, 24 reduced and 19 closed positions. Its largest new stake was Legend Biotech: 3,496,234 shares worth $114M. The largest sale was Apple, an estimated $78.3M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.
- Aaron Cowen's largest Q4 2024 buy was Legend Biotech: 3,496,234 shares worth $114M.
- Aaron Cowen added most to Coca-Cola in Q4 2024, an estimated $35.8M increase.
- Aaron Cowen's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $40.7M.
- Aaron Cowen fully exited Apple in Q4 2024, selling an estimated $78.3M.
- Aaron Cowen's ten largest holdings make up 44% of its $2.93B portfolio in Q4 2024.
- Aaron Cowen opened 17 new positions and closed 19 in Q4 2024.
- Aaron Cowen's portfolio value fell 6.1% quarter-over-quarter to $2.93B.
Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.